(NASDAQ: NXTC) Nextcure's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Nextcure's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NXTC's revenue for 2026 to be $92,311,854, with the lowest NXTC revenue forecast at $92,311,854, and the highest NXTC revenue forecast at $92,311,854. On average, 1 Wall Street analysts forecast NXTC's revenue for 2027 to be $195,813,023, with the lowest NXTC revenue forecast at $195,813,023, and the highest NXTC revenue forecast at $195,813,023.
In 2028, NXTC is forecast to generate $1,132,918,205 in revenue, with the lowest revenue forecast at $1,132,918,205 and the highest revenue forecast at $1,132,918,205.